This WeekI think this will be an interesting week. The MCTO will be removed and that should hopefully free up management to update the market on the two most important issues facing Replicel: What is the status of the Shseido Arbitration and when will the Dermaprecise be presented for FDA Approval.
If the news is good I am thinking this may be last time we see of the share price at this level. This week could also be the last chance to pick up some cheap shares.
The key element here is we need the update.....bring it on !